The VettaFi Autism Impact Index is designed to measure the performance of publicly traded global companies in developed markets that provide products, services, and/or research supporting the autism ecosystem — comprised of individuals on the autism spectrum and the broader neurodivergent community. VettaFi screens the global universe of listed companies using revenue segmentation disclosures, clinical trials activity, product indication filings, and public company filings and investor materials. To be eligible at reconstitution, a company must have a market capitalization of at least $250 million and a three-month average daily trading value of at least $1 million, and its products, services, and/or research must have a material impact on or play a direct role in one or more of three core segments: Drugs & Behavior Therapeutics — Pharmaceuticals, biologics, and clinical services (including ABA, speech, and occupational therapy) addressing autism and related neurodevelopmental and behavioral conditions. Diagnostics & Assessment Tools — Clinical, digital, neurological, and AI-driven tools used in the identification, monitoring, or assessment of autism. Specialized Education & Educational Technology — Education platforms, digital learning systems, curriculum solutions, and school services designed for neurodivergent learners.
